Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Metagenomic analysis reveals a rich bacterial content in high-risk prostate tumors from African men.

Feng Y, Jaratlerdsiri W, Patrick SM, Lyons RJ, Haynes AM, Collins CC, Stricker PD, Bornman MSR, Hayes VM.

Prostate. 2019 Aug 27. doi: 10.1002/pros.23897. [Epub ahead of print]

PMID:
31454437
2.

p53 nuclear accumulation as an early indicator of lethal prostate cancer.

Quinn DI, Stricker PD, Kench JG, Grogan J, Haynes AM, Henshall SM, Grygiel JJ, Delprado W, Turner JJ, Horvath LG, Mahon KL.

Br J Cancer. 2019 Aug 14. doi: 10.1038/s41416-019-0549-8. [Epub ahead of print]

PMID:
31409910
3.

Evaluation of the Protective Ability of the Treponema pallidum subsp. pallidum Tp0126 OmpW Homolog in the Rabbit Model of Syphilis.

Haynes AM, Godornes C, Ke W, Giacani L.

Infect Immun. 2019 Jul 23;87(8). pii: e00323-19. doi: 10.1128/IAI.00323-19. Print 2019 Aug.

PMID:
31182617
4.

Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort.

Blazevski A, Scheltema MJ, Yuen B, Masand N, Nguyen TV, Delprado W, Shnier R, Haynes AM, Cusick T, Thompson J, Stricker P.

Eur Urol Oncol. 2019 May 16. pii: S2588-9311(19)30057-4. doi: 10.1016/j.euo.2019.04.008. [Epub ahead of print]

PMID:
31103721
5.

Non-pathogenic Borrelia burgdorferi expressing Treponema pallidum TprK and Tp0435 antigens as a novel approach to evaluate syphilis vaccine candidates.

Parveen N, Fernandez MC, Haynes AM, Zhang RL, Godornes BC, Centurion-Lara A, Giacani L.

Vaccine. 2019 Mar 22;37(13):1807-1818. doi: 10.1016/j.vaccine.2019.02.022. Epub 2019 Feb 20.

PMID:
30797635
6.

Topical treatment with gallium maltolate reduces Treponema pallidum subsp. pertenue burden in primary experimental lesions in a rabbit model of yaws.

Giacani L, Bernstein LR, Haynes AM, Godornes BC, Ciccarese G, Drago F, Parodi A, Valdevit S, Anselmi L, Tomasini CF, Baca AM.

PLoS Negl Trop Dis. 2019 Jan 2;13(1):e0007076. doi: 10.1371/journal.pntd.0007076. eCollection 2019 Jan.

7.

Reduced sensitivity of multiparametric MRI for clinically significant prostate cancer in men under the age of 50.

Gielchinsky I, Scheltema MJ, Cusick T, Chang J, Shnier R, Moses D, Delprado W, Nguyen Q, Yuen C, Haynes AM, Stricker PD.

Res Rep Urol. 2018 Oct 4;10:145-150. doi: 10.2147/RRU.S169017. eCollection 2018.

8.

Prostate cancer in 432 men aged <50 years in the prostate-specific antigen era: a new outlook.

Gielchinsky I, Chang J, Cusick T, Delprado W, Nguyen Q, Yuen C, Savdie R, Böhm M, Haynes AM, Scheltema MJ, Stricker PD.

BJU Int. 2018 Nov;122 Suppl 5:35-41. doi: 10.1111/bju.14586. Epub 2018 Nov 8.

9.

Identifying the morphologic basis for radiomic features in distinguishing different Gleason grades of prostate cancer on MRI: Preliminary findings.

Penzias G, Singanamalli A, Elliott R, Gollamudi J, Shih N, Feldman M, Stricker PD, Delprado W, Tiwari S, Böhm M, Haynes AM, Ponsky L, Fu P, Tiwari P, Viswanath S, Madabhushi A.

PLoS One. 2018 Aug 31;13(8):e0200730. doi: 10.1371/journal.pone.0200730. eCollection 2018.

10.

Domestic dilemma: when cultivated plants lose their wild side.

Haynes AM.

Conserv Physiol. 2018 Jul 9;6(1):coy039. doi: 10.1093/conphys/coy039. eCollection 2018. No abstract available.

11.

Effects of talactoferrin alpha on lung adenoma prevention in A/J mice June 2, 2016.

Seabloom DE, Galbraith AR, Haynes AM, Fujita AS, Antonides JD, Wuertz BR, Steele VE, Ondrey FG, Wattenberg LW.

Am J Transl Res. 2018 Mar 15;10(3):875-880. eCollection 2018.

12.

Radiomic features on MRI enable risk categorization of prostate cancer patients on active surveillance: Preliminary findings.

Algohary A, Viswanath S, Shiradkar R, Ghose S, Pahwa S, Moses D, Jambor I, Shnier R, Böhm M, Haynes AM, Brenner P, Delprado W, Thompson J, Pulbrock M, Purysko AS, Verma S, Ponsky L, Stricker P, Madabhushi A.

J Magn Reson Imaging. 2018 Feb 22. doi: 10.1002/jmri.25983. [Epub ahead of print]

13.

Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.

Lin HM, Lee BY, Castillo L, Spielman C, Grogan J, Yeung NK, Kench JG, Stricker PD, Haynes AM, Centenera MM, Butler LM, Shreeve SM, Horvath LG, Daly RJ.

Prostate. 2018 Mar;78(4):308-317. doi: 10.1002/pros.23476. Epub 2018 Jan 5.

PMID:
29314097
14.

Superior Biochemical Recurrence and Long-term Quality-of-life Outcomes Are Achievable with Robotic Radical Prostatectomy After a Long Learning Curve-Updated Analysis of a Prospective Single-surgeon Cohort of 2206 Consecutive Cases.

Thompson JE, Egger S, Böhm M, Siriwardana AR, Haynes AM, Matthews J, Scheltema MJ, Stricker PD.

Eur Urol. 2018 May;73(5):664-671. doi: 10.1016/j.eururo.2017.11.035. Epub 2017 Dec 19.

PMID:
29273404
15.

Altered mitochondrial genome content signals worse pathology and prognosis in prostate cancer.

Kalsbeek AMF, Chan EKF, Grogan J, Petersen DC, Jaratlerdsiri W, Gupta R, Lyons RJ, Haynes AM, Horvath LG, Kench JG, Stricker PD, Hayes VM.

Prostate. 2018 Jan;78(1):25-31. doi: 10.1002/pros.23440. Epub 2017 Nov 14.

PMID:
29134670
16.

Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer.

Scheltema MJ, van den Bos W, Siriwardana AR, Kalsbeek AMF, Thompson JE, Ting F, Böhm M, Haynes AM, Shnier R, Delprado W, Stricker PD.

BJU Int. 2017 Nov;120 Suppl 3:51-58. doi: 10.1111/bju.13991. Epub 2017 Sep 19.

17.

Focal irreversible electroporation as primary treatment for localized prostate cancer.

van den Bos W, Scheltema MJ, Siriwardana AR, Kalsbeek AMF, Thompson JE, Ting F, Böhm M, Haynes AM, Shnier R, Delprado W, Stricker PD.

BJU Int. 2018 May;121(5):716-724. doi: 10.1111/bju.13983. Epub 2017 Sep 4.

18.

Initial multicentre experience of 68 gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited.

Siriwardana A, Thompson J, van Leeuwen PJ, Doig S, Kalsbeek A, Emmett L, Delprado W, Wong D, Samaratunga H, Haynes AM, Coughlin G, Stricker P.

BJU Int. 2017 Nov;120(5):673-681. doi: 10.1111/bju.13919. Epub 2017 Jun 20.

19.

Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in patients undergoing radical prostatectomy with long-term follow-up.

Grogan J, Gupta R, Mahon KL, Stricker PD, Haynes AM, Delprado W, Turner J, Horvath LG, Kench JG.

BJU Int. 2017 Nov;120(5):651-658. doi: 10.1111/bju.13857. Epub 2017 Apr 30.

20.

A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy.

van Leeuwen PJ, Hayen A, Thompson JE, Moses D, Shnier R, Böhm M, Abuodha M, Haynes AM, Ting F, Barentsz J, Roobol M, Vass J, Rasiah K, Delprado W, Stricker PD.

BJU Int. 2017 Dec;120(6):774-781. doi: 10.1111/bju.13814. Epub 2017 Mar 31.

21.

Computational imaging reveals shape differences between normal and malignant prostates on MRI.

Rusu M, Purysko AS, Verma S, Kiechle J, Gollamudi J, Ghose S, Herrmann K, Gulani V, Paspulati R, Ponsky L, Böhm M, Haynes AM, Moses D, Shnier R, Delprado W, Thompson J, Stricker P, Madabhushi A.

Sci Rep. 2017 Feb 1;7:41261. doi: 10.1038/srep41261.

22.

Fixed-Dose Combinations of Pioglitazone and Metformin for Lung Cancer Prevention.

Seabloom DE, Galbraith AR, Haynes AM, Antonides JD, Wuertz BR, Miller WA, Miller KA, Steele VE, Miller MS, Clapper ML, O'Sullivan MG, Ondrey FG.

Cancer Prev Res (Phila). 2017 Feb;10(2):116-123. doi: 10.1158/1940-6207.CAPR-16-0232. Epub 2017 Jan 4.

23.

Safety and Preclinical Efficacy of Aerosol Pioglitazone on Lung Adenoma Prevention in A/J Mice.

Seabloom DE, Galbraith AR, Haynes AM, Antonides JD, Wuertz BR, Miller WA, Miller KA, Steele VE, Suen CS, O'Sullivan MG, Ondrey FG.

Cancer Prev Res (Phila). 2017 Feb;10(2):124-132. doi: 10.1158/1940-6207.CAPR-16-0174. Epub 2016 Dec 19.

24.

Radiomic features for prostate cancer detection on MRI differ between the transition and peripheral zones: Preliminary findings from a multi-institutional study.

Ginsburg SB, Algohary A, Pahwa S, Gulani V, Ponsky L, Aronen HJ, Boström PJ, Böhm M, Haynes AM, Brenner P, Delprado W, Thompson J, Pulbrock M, Taimen P, Villani R, Stricker P, Rastinehad AR, Jambor I, Madabhushi A.

J Magn Reson Imaging. 2017 Jul;46(1):184-193. doi: 10.1002/jmri.25562. Epub 2016 Dec 19.

25.

Loss of AZGP1 as a Superior Predictor of Relapse in Margin-Positive Localized Prostate Cancer.

Bruce HM, Stricker PD, Gupta R, Savdie RR, Haynes AM, Mahon KL, Lin HM, Kench JG, Horvath LG.

Prostate. 2016 Dec;76(16):1491-1500. doi: 10.1002/pros.23233. Epub 2016 Jul 30.

PMID:
27473574
26.

Mutational load of the mitochondrial genome predicts pathological features and biochemical recurrence in prostate cancer.

Kalsbeek AM, Chan EF, Grogan J, Petersen DC, Jaratlerdsiri W, Gupta R, Lyons RJ, Haynes AM, Horvath LG, Kench JG, Stricker PD, Hayes VM.

Aging (Albany NY). 2016 Oct 5;8(11):2702-2712. doi: 10.18632/aging.101044.

27.

AutoStitcher: An Automated Program for Efficient and Robust Reconstruction of Digitized Whole Histological Sections from Tissue Fragments.

Penzias G, Janowczyk A, Singanamalli A, Rusu M, Shih N, Feldman M, Stricker PD, Delprado W, Tiwari S, Böhm M, Haynes AM, Ponsky L, Viswanath S, Madabhushi A.

Sci Rep. 2016 Jul 26;6:29906. doi: 10.1038/srep29906.

28.

What Is Your Diagnosis?

Mills TL, Haynes AM, Garcia EB, Biller DS.

J Am Vet Med Assoc. 2016 Jul 15;249(2):149-51. doi: 10.2460/javma.249.2.149. No abstract available.

PMID:
27379589
29.

Occurrence and Clinicopathologic Features of Splenic Neoplasia Based on Body Weight: 325 Dogs (2003-2013).

Sherwood JM, Haynes AM, Klocke E, Higginbotham ML, Thomson EM, Weng HY, Towle Millard HA.

J Am Anim Hosp Assoc. 2016 Jul-Aug;52(4):220-6. doi: 10.5326/JAAHA-MS-6346. Epub 2016 Jun 3.

PMID:
27259024
30.

Predicting Low-Risk Prostate Cancer from Transperineal Saturation Biopsies.

van Leeuwen PJ, Siriwardana A, Roobol M, Ting F, Nieboer D, Thompson J, Delprado W, Haynes AM, Brenner P, Stricker P.

Prostate Cancer. 2016;2016:7105678. doi: 10.1155/2016/7105678. Epub 2016 Apr 11.

31.

The Diagnostic Performance of Multiparametric Magnetic Resonance Imaging to Detect Significant Prostate Cancer.

Thompson JE, van Leeuwen PJ, Moses D, Shnier R, Brenner P, Delprado W, Pulbrook M, Böhm M, Haynes AM, Hayen A, Stricker PD.

J Urol. 2016 May;195(5):1428-1435. doi: 10.1016/j.juro.2015.10.140. Epub 2015 Oct 31.

PMID:
26529298
32.

Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control.

Ting F, Tran M, Böhm M, Siriwardana A, Van Leeuwen PJ, Haynes AM, Delprado W, Shnier R, Stricker PD.

Prostate Cancer Prostatic Dis. 2016 Mar;19(1):46-52. doi: 10.1038/pcan.2015.47. Epub 2015 Oct 13.

PMID:
26458959
33.

Tumor volume in insignificant prostate cancer: Increasing the threshold is a safe approach to reduce over-treatment.

Ting F, van Leeuwen PJ, Delprado W, Haynes AM, Brenner P, Stricker PD.

Prostate. 2015 Nov;75(15):1768-73. doi: 10.1002/pros.23062. Epub 2015 Aug 18.

PMID:
26282713
34.

Combination of multiparametric MRI and transperineal template-guided mapping biopsy of the prostate to identify candidates for hemi-ablative focal therapy.

Tran M, Thompson J, Böhm M, Pulbrook M, Moses D, Shnier R, Brenner P, Delprado W, Haynes AM, Savdie R, Stricker PD.

BJU Int. 2016 Jan;117(1):48-54. doi: 10.1111/bju.13090. Epub 2015 May 11.

35.

Extraprostatic extension (EPE) of prostatic carcinoma: is its proximity to the surgical margin or Gleason score important?

Gupta R, O'Connell R, Haynes AM, Stricker PD, Barrett W, Turner JJ, Delprado W, Horvath LG, Kench JG.

BJU Int. 2015 Sep;116(3):343-50. doi: 10.1111/bju.12911. Epub 2014 Dec 15.

36.

Medium-term oncological outcomes for extended vs saturation biopsy and transrectal vs transperineal biopsy in active surveillance for prostate cancer.

Thompson JE, Hayen A, Landau A, Haynes AM, Kalapara A, Ischia J, Matthews J, Frydenberg M, Stricker PD.

BJU Int. 2015 Jun;115(6):884-91. doi: 10.1111/bju.12858. Epub 2014 Oct 23.

37.

Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study.

Thompson JE, Moses D, Shnier R, Brenner P, Delprado W, Ponsky L, Pulbrook M, Böhm M, Haynes AM, Hayen A, Stricker PD.

J Urol. 2014 Jul;192(1):67-74. doi: 10.1016/j.juro.2014.01.014. Epub 2014 Feb 8.

PMID:
24518762
38.

A multinational, multi-institutional study comparing positive surgical margin rates among 22393 open, laparoscopic, and robot-assisted radical prostatectomy patients.

Sooriakumaran P, Srivastava A, Shariat SF, Stricker PD, Ahlering T, Eden CG, Wiklund PN, Sanchez-Salas R, Mottrie A, Lee D, Neal DE, Ghavamian R, Nyirady P, Nilsson A, Carlsson S, Xylinas E, Loidl W, Seitz C, Schramek P, Roehrborn C, Cathelineau X, Skarecky D, Shaw G, Warren A, Delprado WJ, Haynes AM, Steyerberg E, Roobol MJ, Tewari AK.

Eur Urol. 2014 Sep;66(3):450-6. doi: 10.1016/j.eururo.2013.11.018. Epub 2013 Nov 24.

PMID:
24290695
39.

Superior quality of life and improved surgical margins are achievable with robotic radical prostatectomy after a long learning curve: a prospective single-surgeon study of 1552 consecutive cases.

Thompson JE, Egger S, Böhm M, Haynes AM, Matthews J, Rasiah K, Stricker PD.

Eur Urol. 2014 Mar;65(3):521-31. doi: 10.1016/j.eururo.2013.10.030. Epub 2013 Oct 31.

PMID:
24287319
40.

A novel method of bladder neck imbrication to improve early urinary continence following robotic-assisted radical prostatectomy.

Beattie K, Symons J, Chopra S, Yuen C, Savdie R, Thanigasalam R, Haynes AM, Matthews J, Brenner PC, Rasiah K, Sutherland RL, Stricker PD.

J Robot Surg. 2013 Jun;7(2):193-9. doi: 10.1007/s11701-012-0371-2. Epub 2012 Jul 26.

PMID:
27000912
41.

Outcomes of transperineal template-guided prostate biopsy in 409 patients.

Symons JL, Huo A, Yuen CL, Haynes AM, Matthews J, Sutherland RL, Brenner P, Stricker PD.

BJU Int. 2013 Sep;112(5):585-93. doi: 10.1111/j.1464-410X.2012.11657.x. Epub 2013 Apr 3.

42.

High-dose rate brachytherapy compared with open radical prostatectomy for the treatment of high-risk prostate cancer: 10 year biochemical freedom from relapse.

Savdie R, Symons J, Spernat D, Yuen C, Pe Benito RA, Haynes AM, Matthews J, Rasiah KK, Jagavkar RS, Yu C, Fogarty G, Kattan MW, Brenner P, Sutherland RL, Stricker PD.

BJU Int. 2012 Dec;110 Suppl 4:71-6. doi: 10.1111/j.1464-410X.2012.11480.x.

43.

Location and pathological characteristics of cancers in radical prostatectomy specimens identified by transperineal biopsy compared to transrectal biopsy.

Hossack T, Patel MI, Huo A, Brenner P, Yuen C, Spernat D, Mathews J, Haynes AM, Sutherland R, del Prado W, Stricker P.

J Urol. 2012 Sep;188(3):781-5. doi: 10.1016/j.juro.2012.05.006. Epub 2012 Jul 20.

PMID:
22819419
44.

High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy.

Savdie R, Horvath LG, Benito RP, Rasiah KK, Haynes AM, Chatfield M, Stricker PD, Turner JJ, Delprado W, Henshall SM, Sutherland RL, Kench JG.

BJU Int. 2012 Jun;109(12):1794-800. doi: 10.1111/j.1464-410X.2011.10572.x. Epub 2011 Oct 12.

45.

The impact of nerve sparing on incidence and location of positive surgical margins in radical prostatectomy.

Moore BM, Savdie R, PeBenito RA, Haynes AM, Matthews J, Delprado W, Rasiah KK, Stricker PD.

BJU Int. 2012 Feb;109(4):533-8. doi: 10.1111/j.1464-410X.2011.10361.x. Epub 2011 Jun 28.

46.

Epigenetic deregulation across chromosome 2q14.2 differentiates normal from prostate cancer and provides a regional panel of novel DNA methylation cancer biomarkers.

Devaney J, Stirzaker C, Qu W, Song JZ, Statham AL, Patterson KI, Horvath LG, Tabor B, Coolen MW, Hulf T, Kench JG, Henshall SM, Pe Benito R, Haynes AM, Mayor R, Peinado MA, Sutherland RL, Clark SJ.

Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):148-59. doi: 10.1158/1055-9965.EPI-10-0719. Epub 2010 Nov 23.

47.

Should experienced open prostatic surgeons convert to robotic surgery? The real learning curve for one surgeon over 3 years.

Doumerc N, Yuen C, Savdie R, Rahman MB, Rasiah KK, Pe Benito R, Delprado W, Matthews J, Haynes AM, Stricker PD.

BJU Int. 2010 Aug;106(3):378-84. doi: 10.1111/j.1464-410X.2009.09158.x. Epub 2010 Jan 8.

48.

Stage migration in localized prostate cancer has no effect on the post-radical prostatectomy Kattan nomogram.

Thanigasalam R, Rasiah KK, Stricker PD, Haynes AM, Sutherland SI, Sutherland RL, Henshall SM, Horvath LG.

BJU Int. 2010 Mar;105(5):642-7. doi: 10.1111/j.1464-410X.2009.08842.x. Epub 2009 Sep 14.

49.

Cross-sectional analysis of sexual function after prostate brachytherapy.

Finney G, Haynes AM, Cross P, Brenner P, Boyn A, Stricker P.

Urology. 2005 Aug;66(2):377-81.

PMID:
16098365
50.

Prognostic significance of Gleason pattern in patients with Gleason score 7 prostate carcinoma.

Rasiah KK, Stricker PD, Haynes AM, Delprado W, Turner JJ, Golovsky D, Brenner PC, Kooner R, O'Neill GF, Grygiel JJ, Sutherland RL, Henshall SM.

Cancer. 2003 Dec 15;98(12):2560-5.

Supplemental Content

Loading ...
Support Center